LV12350A - Heptapeptida oksitocina analogi - Google Patents

Heptapeptida oksitocina analogi

Info

Publication number
LV12350A
LV12350A LV990077A LV990077A LV12350A LV 12350 A LV12350 A LV 12350A LV 990077 A LV990077 A LV 990077A LV 990077 A LV990077 A LV 990077A LV 12350 A LV12350 A LV 12350A
Authority
LV
Latvia
Prior art keywords
moiety
alfa
aminoacid
synthesis
heptapeptide
Prior art date
Application number
LV990077A
Other languages
English (en)
Other versions
LV12350B (lv
Inventor
Per Melin
Anders Nilsson
Jerzy Trojnar
Carl-Johan Aurell
Pierre Riviere
Robert Haigh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of LV12350A publication Critical patent/LV12350A/lv
Publication of LV12350B publication Critical patent/LV12350B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
LVP-99-77A 1996-11-26 1999-04-30 Heptapeptīda oksitocīna analogi LV12350B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
LV12350A true LV12350A (lv) 1999-09-20
LV12350B LV12350B (lv) 1999-11-20

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-77A LV12350B (lv) 1996-11-26 1999-04-30 Heptapeptīda oksitocīna analogi

Country Status (35)

Country Link
US (1) US6143722A (lv)
EP (1) EP0938496B1 (lv)
JP (1) JP3405460B2 (lv)
KR (1) KR100463132B1 (lv)
CN (1) CN1129606C (lv)
AR (1) AR008531A1 (lv)
AT (1) ATE242264T1 (lv)
AU (1) AU713424B2 (lv)
BR (1) BR9713366B1 (lv)
CA (1) CA2272990C (lv)
CZ (1) CZ299532B6 (lv)
DE (1) DE69722651T2 (lv)
DK (1) DK0938496T3 (lv)
EE (1) EE03832B1 (lv)
ES (1) ES2203823T3 (lv)
HK (1) HK1022481A1 (lv)
HR (1) HRP970630B1 (lv)
HU (1) HU228568B1 (lv)
IL (1) IL129519A (lv)
LT (1) LT4650B (lv)
LV (1) LV12350B (lv)
MY (1) MY125555A (lv)
NO (1) NO321380B1 (lv)
NZ (1) NZ336445A (lv)
PL (1) PL189292B1 (lv)
PT (1) PT938496E (lv)
RO (1) RO120772B1 (lv)
RU (1) RU2180668C2 (lv)
SE (1) SE9604341D0 (lv)
SI (1) SI20026B (lv)
SK (1) SK283800B6 (lv)
TR (1) TR199901028T2 (lv)
UA (1) UA54459C2 (lv)
WO (1) WO1998023636A1 (lv)
ZA (1) ZA9710518B (lv)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
EP1480998B1 (en) * 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
US20060014147A1 (en) * 2002-05-02 2006-01-19 Stefan Golz Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
CA2718148C (en) * 2008-03-31 2017-11-07 Ferring B.V. Oxytocin analogues
PT2712622T (pt) 2008-05-21 2016-10-13 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono tranquilo
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
PE20130398A1 (es) 2010-07-15 2013-04-10 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
CN103415530A (zh) 2011-03-09 2013-11-27 Jitsubo株式会社 新型的含有非肽性交联结构的交联肽、以及该交联肽的合成方法和用于该方法的新型有机化合物
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533A1 (en) * 2014-12-22 2019-06-26 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR20180059549A (ko) 2015-10-06 2018-06-04 훼링 비.브이. 바루시반 및 이의 중간체의 새로운 제조 방법
HRP20220673T1 (hr) 2016-01-04 2022-07-08 Merck Serono S.A. L-valinat derivata hidroksipropiltiazolidin karboksamida, njegova sol i njegov kristalni oblik
CN115569132A (zh) 2016-07-21 2023-01-06 奥布赛瓦股份公司 促进胚胎植入和预防流产的催产素拮抗剂给药方案
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
AU2021218895A1 (en) 2020-02-10 2022-09-15 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
JP3405460B2 (ja) 2003-05-12
ES2203823T3 (es) 2004-04-16
CZ183299A3 (cs) 2000-05-17
ZA9710518B (en) 1998-06-10
DE69722651D1 (en) 2003-07-10
PL189292B1 (pl) 2005-07-29
PT938496E (pt) 2003-10-31
SK70499A3 (en) 2000-10-09
NO992532L (no) 1999-05-26
KR100463132B1 (ko) 2004-12-23
SI20026A (sl) 2000-02-29
AU713424B2 (en) 1999-12-02
SI20026B (sl) 2000-06-30
NO992532D0 (no) 1999-05-26
EP0938496B1 (en) 2003-06-04
HU228568B1 (en) 2013-04-29
IL129519A0 (en) 2000-02-29
LT99052A (en) 2000-01-25
JP2000507617A (ja) 2000-06-20
EP0938496A1 (en) 1999-09-01
MY125555A (en) 2006-08-30
DE69722651T2 (de) 2004-04-08
NZ336445A (en) 2000-06-23
US6143722A (en) 2000-11-07
ATE242264T1 (de) 2003-06-15
DK0938496T3 (da) 2003-10-06
BR9713366B1 (pt) 2010-05-18
WO1998023636A1 (en) 1998-06-04
AU5142998A (en) 1998-06-22
TR199901028T2 (xx) 1999-07-21
CA2272990A1 (en) 1998-06-04
CN1238781A (zh) 1999-12-15
HUP0000577A2 (hu) 2000-11-28
CA2272990C (en) 2002-11-19
LV12350B (lv) 1999-11-20
AR008531A1 (es) 2000-01-19
EE9900210A (et) 1999-12-15
KR20000069045A (ko) 2000-11-25
HRP970630A2 (en) 1998-10-31
SK283800B6 (sk) 2004-02-03
NO321380B1 (no) 2006-05-02
IL129519A (en) 2004-09-27
CN1129606C (zh) 2003-12-03
HRP970630B1 (en) 2002-04-30
BR9713366A (pt) 2000-01-25
RO120772B1 (ro) 2006-07-28
EE03832B1 (et) 2002-08-15
HUP0000577A3 (en) 2001-02-28
LT4650B (lt) 2000-04-25
UA54459C2 (uk) 2003-03-17
RU2180668C2 (ru) 2002-03-20
HK1022481A1 (en) 2000-08-11
CZ299532B6 (cs) 2008-08-27
SE9604341D0 (sv) 1996-11-26

Similar Documents

Publication Publication Date Title
LV12350A (lv) Heptapeptida oksitocina analogi
HUP9901209A2 (hu) Opioid analóg peptid vegyületek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HK1045161A1 (en) Lhrh antagonist peptides lhrh
MX9801716A (es) Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
IL61923A0 (en) Angiotensin-ii analogues containing an ester group in position 8,and process for the preparation thereof
ES2179318T3 (es) Derivados de acido cinamico y su uso como antagonistas de integrina.
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ES2187958T3 (es) Antagonistas de gnrh.
EP0334244A3 (en) Bradykinin antagonist peptides
CA2109322C (en) Bombesin analogs
DE69723728D1 (de) Totalsynthese des amino hip analogen von didemnin a
ATE14226T1 (de) Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
US5502035A (en) N-terminus modified analogs of LHRH
RU94045881A (ru) Производные пептидов, способ получения, фармацевтическая композиция, способ лечения
US5428018A (en) Phenylalanine analogs of bombesin
ES471672A1 (es) Un procedimiento para la preparacion de un peptido
EP0738154A1 (en) N-terminus modified analogs of lhrh
CA2076749A1 (en) Vasoactive vasotocin derivatives
ZA877862B (en) The synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method
EP0234935A3 (en) Vasopressin compounds
ATE46347T1 (de) Immunostimulierende peptide.
DE3886656T2 (de) Lösungssynthese eines Oktapeptids.
EP0406931A3 (en) New analogues of all-bond retroinverted thymopentin, the method for the synthesis of the same and their employment for the preparation of pharmaceutical compositions
NO931091L (no) Analoger av sykloinopeptid a og anvendelse derav